Educational overview · Approx. 4 min read · illustrative, not advice
Fourteen percent of GLP-1 users told KFF they stopped because of cost. That is a fact about the category's affordability pressure — not a prediction about what any particular program will experience.
The one number to design around
KFF found that among GLP-1 users, 56% reported difficulty affording the drug, 25% found it very difficult, 27% had insurance but paid the entire cost themselves, and 14% stopped taking it because of cost.
Read that as an operating fact rather than a market fact. In a cash-pay program, cost pressure is the leading documented reason people leave, and it is not primarily a clinical failure. It is an affordability and perceived-value failure, which means it is addressable by design rather than only by discounting.
We are not going to convert that into a churn projection, a retention curve, or any figure attached to your business, because any such number would be an earnings representation dressed as an operating metric.
Why retention carries more weight here than in most service businesses
Three structural reasons. Acquisition in this category is expensive and getting more competitive as manufacturers market directly. The program's value compounds over time, so a member who leaves in month two never experiences the thing you actually sold. And referral, which is the cheapest acquisition source on page ten, is generated almost entirely by members who stayed long enough to have an experience worth describing.
That makes retention the input to acquisition rather than a separate department. A business with weak retention is a business that must buy every member it will ever have, forever, at a rising price.
The first thirty days decide most of it
The pattern across service programs with a clinical component is that early experience predicts duration disproportionately. Practically, the first thirty days should do four things: set an accurate expectation of what happens and when, deliver a visible early win that is not weight on a scale, make contact frequent enough that nobody feels abandoned between clinical visits, and give the member a named human who knows their situation.
The failure pattern is equally consistent: an intensive sales conversation, a clinical visit, a shipment, and then silence. The member's next meaningful interaction is a card charge, which is the worst possible next interaction.
Note that KFF found 34% of employers covering these drugs required a provider visit or lifestyle program participation. Sophisticated payers have concluded that a structured program alongside medication is worth mandating. That is a demand signal for exactly the wrapper described here.
Design decisions that affect duration
Program length and how it is framed. A defined program with phases and a completion point behaves differently from an indefinite subscription, both in how it is sold and in how people leave it.
What is included beyond the medication component: labs and monitoring cadence, nutrition support, movement, sleep, behaviour work, and the coaching layer described on page seven. The more of the member's actual problem you address, the less the program's perceived value is pinned to one line item whose price is falling.
Cost structure and transparency. Surprise charges are a retention event. So is a member discovering that the same molecule is available direct at a lower price, if you never explained what else they were paying for.
And a real offboard. People leave. A program that ends well produces referrals and returns; one that ends in a failed card and an ignored email produces neither, and occasionally produces a complaint.
What to measure
Duration by cohort, stated reason for departure captured at the moment of departure rather than reconstructed later, contact frequency in the first thirty days, and the proportion of departures citing cost specifically. That last one tells you whether your problem is price, perceived value, or program design, and those three have completely different fixes.
We publish no benchmarks for any of them. Measure your own, compare to your own prior cohorts, and be suspicious of anyone in this category who hands you a retention figure they cannot substantiate.
- KFF Health Tracking Poll (fielded October 27-November 2, 2025) — Among GLP-1 users, 56% reported difficulty affording the drug, 25% very difficult, 27% had insurance but paid the entire cost themselves, and 14% stopped taking it because of cost. (source) [VERIFIED]
- KFF 2025 Employer Health Benefits Survey — 34% of firms covering GLP-1 agonists for weight loss required a provider visit or lifestyle program participation as a condition of coverage. (source) [VERIFIED]
- Reasoned from KFF affordability data and category acquisition dynamics — Cost-driven discontinuation is primarily an affordability and perceived-value problem addressable through program design rather than solely through price. [INFERENCE]